Abstract The current understanding of the pathophysiology of myofascial pain and the mechanism of botulinum neurotoxin (BoNT) suggest that BoNT may be well suited to the treatment of back pain. The few randomized controlled trials that have been done to evaluate the efficacy of BoNT in the treatment of myofascial low back pain have shown some promising results. Results from the more numerous trials of BoNT for treatment of myofascial thoracic and neck pain have only shown trends toward the efficacy of BoNT treatments compared with control treatments.
Introduction
Back pain is associated with a significant socioeconomic and health impact. Health care expenditure for back pain in the USA was estimated at $90.7 billion in 1998 [1] . The annual prevalence of low back pain ranges from 15 to 45 %. The resulting loss of productivity is evidenced by an average of nine workdays missed per year in the USA for individuals with back pain [2] . The incidence of neck pain over a 1-year period ranged from 27.1 % in Norway to 47.8 % in Quebec, Canada. Between 11 and 14 % of workers were limited in their activities because of neck pain [3] . In 1990 there were almost 15 million visits to physicians' offices for ''mechanical'' low back pain [4] . Opioids are a common form of medical treatment for back pain. The mean annual prescription medication cost is eight times higher for opioid abusers versus nonabusers, $15,884 versus $1,830 [5] . The treatment and productivity costs associated with back pain have continued to rise despite an ongoing effort to describe the pathophysiology of different types of back pain and identify treatments with significant and lasting benefit.
Myofascial pain is defined as pain that originates from trigger points, taught bands of muscle that reproduce pain patterns on palpation. Myofascial pain can be present with or without other pain generators and often causes referred pain to the surrounding muscles. The cause of myofascial pain is controversial, but studies have elucidated at least part of the pathophysiological mechanism involved. Pertinent to this review are the findings of a pathological increase in the release of acetylcholine (ACh) by the nerve terminal evidenced in electrodiagnostic studies of the affected resting muscle [6 • ]. A positive-feedback loop has been proposed to explain the persistence of increased ACh release by involved trigger points. In the proposed feedback loop, local ischemia and increased metabolism are caused by sustained sarcomere contraction leading to energy crisis of the tissue. Release of sensitizing substances then generates pain and propagates increased ACh release [6 • ]. Botulinum neurotoxin (BoNT) inhibits the release of ACh from the nerve terminal and so theoretically should be able to interfere with the proposed positive-feedback loop.
BoNT has been investigated in the treatment of back pain, muscle disorders, and headaches. It has been shown to be effective in the treatment of cervical dystonia by relieving both muscle spasticity and pain [7] . The mechanism of BoNT has been well demonstrated as muscle relaxation, but studies also suggest a separate analgesic mechanism through inhibition of the release of substance P [8] . The following is a review of the literature on the efficacy of BoNT in the treatment of back pain.
Literature Search
The electronic literature was searched using the keywords ''botulinum toxin, '' ''Botox,'' ''low pack pain,'' ''neck pain,'' and ''myofascial pain'' in the PubMed database.
Additional studies were included after reviewing the bibliographies of relevant articles. Studies were excluded from this review if they were not randomized controlled trials (RCTs) comparing BoNT with alternative treatments or if they included subjects with fibromyalgia or subjects with pain generators other than myofascial pain. The literature was searched up to February 1, 2013.
Low Back Pain
Few RCTs of intramuscular injections of BoNT for the treatment of low back pain have been performed (Table 1) . The subjects included in these three studies had low back pain or symptoms of sciatica for over 6 months. The acute and subacute low back pain populations were not represented in these studies. 
Thoracic and Neck Pain
The studies included in Table 2 are all RCTs, but their power, methods, and outcomes are quite different. All studies focused on enrolling participants with chronic myofascial pain, but the participants differed widely in the severity of pain and number of trigger points reported and treated. Each study had at least one outcome measure that was a subjective rating scale, including a VAS, an efficacy of treatment verbal scale, and a pain self-rating scale. Additional outcomes could not be compared given the wide variety of measures reported, including SF-36, number of analgesics used per day, pressure pain thresholds, Beck Depression Inventory, number of days/weeks without pain, and Neck Disability Index. Some of these additional outcomes showed promising trends or statistical significance in favor of BoNT treatment, such as taking less analgesic medication per day (Schnider et et al. [18] ), having fewer days with pain per week (Gobel et al. [15] ), and improvements on the SF-36 (Lew et al. [16] ).
No study showed an overall statistically significant difference between treatment and control groups. Gobel et al. [15 • • ] reported a short period of statistically significant difference in the mean reduction of pain scores between the two groups studied from week 5 to week 8. This study was the highest powered and this result is consistent with the expected time of onset and maximum effect of BoNT, making it a potentially positive result for comparative efficacy of BoNT. From the results of Gobel et al. from a clinical relevance standpoint, the overall improvement in VAS score at 4 weeks was 30 % for the BoNT group and 17 % for the saline group. A13 percentage point difference in mean VAS score between the two groups, although statistically significant, may not be clinically significant. Fortunately, mean scores do not predict the potential for clinically relevant response to treatment for an individual.
Conclusions
Despite the small number of patients treated in the RCTs of intramuscular injections of BoNT for the treatment of low back pain, two of the three studies discussed showed Compared with low back pain, a larger number of patients have been treated in RCTs of intramuscular injection of BoNT for the treatment of myofascial neck and upper back pain. In many cases both BoNT and control treatments produced more than 30 % improvement in subjective pain scores compared with baseline scores. Reports on the comparative efficacy of BoNT and control treatments have only shown trends toward the superiority of BoNT. These results may indicate that the physiologic effects of BoNT on the myofascial pain process are not as important as the simple intervention of needling or injection of NaCl or lidocaine. They could also indicate a poor understanding of which subpopulation of patients with myofascial pain will respond to BoNT. The methods varied widely in BoNT dose, co-interventions, pain severity, chronicity, and number of trigger points treated, so aggregate data evaluation would not be meaningful. Further studies of BoNT treatment for myofascial neck and upper back pain may be able to better characterize the optimal treatment population, dose, and method of administration. It appears that only a small subpopulation of patients with myofascial neck and upper back pain may receive comparative benefit from BoNT treatment given the lack of a statistically significant difference found in multiple studies. 
